Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cocktail targets Hard-to-Treat brain cancer

NCT ID NCT03703167

First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This early-phase trial tested a combination of three drugs (ibrutinib, rituximab, and lenalidomide) in 25 adults with recurrent or treatment-resistant central nervous system lymphoma. The main goal was to find the safest dose of ibrutinib when given with the other two drugs. Researchers also tracked how long the cancer stayed under control. The study is complete and provides safety data for this combination approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.